Wilhelmus Groenhuysen Net Worth

The estimated Net Worth of Wilhelmus Cm Groenhuysen is at least $19.2 million dollars as of 5 June 2024. Mr. Groenhuysen owns over 124,373 units of NovoCure Ltd stock worth over $2,142,947 and over the last 9 years he sold NVCR stock worth over $12,877,460. In addition, he makes $4,187,080 as Chief Operating Officer at NovoCure Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Groenhuysen NVCR stock SEC Form 4 insiders trading

Wilhelmus has made over 49 trades of the NovoCure Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 124,373 units of NVCR stock worth $2,838,192 on 5 June 2024.

The largest trade he's ever made was exercising 124,373 units of NovoCure Ltd stock on 5 June 2024 worth over $2,838,192. On average, Wilhelmus trades about 15,493 units every 29 days since 2016. As of 5 June 2024 he still owns at least 124,373 units of NovoCure Ltd stock.

You can see the complete history of Mr. Groenhuysen stock trades at the bottom of the page.

Wilhelmus Groenhuysen biography

Wilhelmus Groenhuysen has been appointed as Chief Operating Officer of the Company effective 9/1/2020. Mr. Groenhuysen has served as the Company's Chief Financial Officer since 2012. He has served on the Board of Optinose Inc., a commercial-stage specialty pharmaceuticals company, since October 2017. From 2007 to 2011, Mr. Groenhuysen worked for Cephalon, Inc., a U.S. biopharmaceutical company, last serving as executive vice president and chief financial officer, where he had responsibility for worldwide finance, commercial operations and risk management. From 1987 to 2007, Mr. Groenhuysen worked for Philips Group in various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to chief financial officer and senior vice president of Philips Electronics North America Corporation. Mr. Groenhuysen holds a Master's Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.

What is the salary of Wilhelmus Groenhuysen?

As the Chief Operating Officer of NovoCure Ltd, the total compensation of Wilhelmus Groenhuysen at NovoCure Ltd is $4,187,080. There are 3 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.

How old is Wilhelmus Groenhuysen?

Wilhelmus Groenhuysen is 62, he's been the Chief Operating Officer of NovoCure Ltd since 2020. There are 5 older and 17 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.

What's Wilhelmus Groenhuysen's mailing address?

Wilhelmus's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.

Insiders trading at NovoCure Ltd

Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... et Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.

What does NovoCure Ltd do?

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Complete history of Mr. Groenhuysen stock trades at NovoCure Ltd et OptiNose Inc

NovoCure Ltd executives and stock owners

NovoCure Ltd executives and other stock owners filed with the SEC include:

• William Doyle,
  Executive Chairman of the Board
• Asaf Danziger,
  President, Chief Executive Officer, Director
• Michael Ambrogi,
  Vice President - Senior Technology Fellow
• Wilhelmus Groenhuysen,
  Chief Operating Officer
• Pritesh Shah,
  Chief Commercial Officer
• Asaf Danziger,
  Pres, CEO & Director
• William F. Doyle,
  Exec. Chairman
• Wilhelmus C. M. Groenhuysen,
  Chief Operating Officer
• Todd C. Longsworth,
  Gen. Counsel
• Ashley Cordova,
  CFO & VP of Investor Relations
• Pritesh Shah,
  Chief Commercial Officer
• William Vernon,
  Lead Independent Director
• Jeryl Hilleman,
  Independent Director
• Martin Madden,
  Independent Director
• Sherilyn McCoy,
  Independent Director
• David Hung,
  Independent Director
• Kinyip Gabriel Leung,
  Independent Director
• Frank Leonard,
  Chief Development Officer
• Todd Longsworth,
  General Counsel
• Ely Benaim,
  Chief Medical Officer
• Ashley Cordova,
  Chief Financial Officer
• Dr. Ely Benaim M.D.,
  Chief Medical Officer
• Barak Ben Arye,
  Gen. Counsel
• Ingrid Goldberg,
  VP of Investor Relations
• Prof. Yoram Palti M.D., Ph.D.,
  Founder & CTO
• Uri Weinberg M.D., Ph.D.,
  Chief Science Officer
• Dr. Ely Benaim,
  Chief Medical Officer
• William Patrick Burke,
  Chief HR Officer
• Prof. Yoram Palti,
  Founder & CTO
• Timothy J Scannell,
  
• Eilon D. Kirson,
  Chief Scientific Officer
• Gert L.Volati Ltd Perlhagen,
  
• Peter M. Melnyk,
  Chief Commercial Officer
• Yoram Palti,
  Chief Technology Officer
• Charles G Iii Phillips,
  Director
• Louis J Jr Lavigne,
  Director
• Ltd Volati,
  10% owner
• William Fwfd Ventures Fund ...,
  
• Gert L. Perlhagen,
  Director
• William T. Burkoth,
  Director
• Capital Vii, L.P.Pomona Cap...,
  
• Moshe Giladi,
  Chief Science Officer
• Nicolas Leupin,
  Chief Medical Officer
• Robert J Jr Mylod,
  Director
• Timothy J. Langloss,
  Director
• Hansjoerg Wyss,
  10% owner
• Allyson J Ocean,
  
• William Patrick Burke,
  Chief Human Resources Officer
• Uri Weinberg,
  Chief Innovation Officer
• W Anthony Vernon,
  
• Kristin Stafford,
  
• Gabriel Leung,
  
• Arye Barak Ben,
  General Counsel
• Michal Nath Puri,
  Chief Human Resources Officer